| Primary information |
|---|
| sequence ID | Seq_3359 |
| Peptide sequence | HAAYHPF |
| CancerPDF_ID | CancerPDF_ID46, CancerPDF_ID1059, CancerPDF_ID11546, |
| PMID | 16896061,16395409,26992070 |
| Protein Name | Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4 protein |
| UniprotKB Entry Name | ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN |
| Fluid | Serum,Serum,Serum |
| M/Z | 842.4,842.4,NA |
| Charge | 1,1,NA |
| Mass (in Da) | 842.39,NA,842.3968371 |
| fdr | NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS/MS |
| Quantification Technique | NA,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID46, CancerPDF_ID1059, CancerPDF_ID11546, |
| p-Value | 1.00E-05,2.73E-12,NA |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),SEQUEST and Maxquant |
| Length | 7,7,7 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Melanoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database |
| Modification | NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",8 cancer samples and 4 healthy samples |
| Regulation | NA,"Upregulated in Prostate cancer vs normal,Downregulated in Bladder cancer vs normal with Ratio of median intensity (patients/Controls) =1.49, 0.01 and 1.04 in prostate, bladder and breast cancer respectively","Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." |
| Validation | Independent validation,Independent validation,na |
| Sensitivity | 95% on independent dataset,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA |
| Specificity | 95% on independent dataset,NA,NA |
| Accuracy | NA,97.5 % on validation dataset,NA |
| Peptide Atlas | NA |
| IEDB | |